Guillaume Connan

Director Ejecutivo en

Helse SAS

Health Technology

Commercial Services

Finance

Perfil

Guillaume Connan is currently the Chairman at Chabé Limousines SAS, Chairman at Connan Bonvallet Conseil, Director at Galien Développement SA, and Managing Director at Helse SAS since 2012.
He previously worked as Chairman at Xeltis AG, Director at Nautilus Biotech SA, Director-Investments at Matignon Investissement et Gestion SAS from 2000 to 2010, and Director at Kaneka Eurogentec SA. He also briefly served as Director at QIAGEN Marseille SA in 2010.
Mr. Connan received his undergraduate degree and MBA from École des Hautes Études Commerciales de Paris.

Cargos activos de Guillaume Connan

Empresas	Cargo	Inicio
Helse SAS Helse SAS Investment ManagersFinance Acts as an alternative investment manager	Director Ejecutivo	09/05/2011
Chabé Limousines SAS Chabé Limousines SAS Other TransportationTransportation Provides private chauffeur services	Presidente	-
Connan Bonvallet Conseil Connan Bonvallet Conseil Miscellaneous Commercial ServicesCommercial Services Provides business and management consulting services	Presidente	-

Todos los cargos activos de Guillaume Connan

Antiguos cargos conocidos de Guillaume Connan.

Empresas	Cargo	Fin
Nautilus Biotech SA Nautilus Biotech SA Pharmaceuticals: MajorHealth Technology Develops and markets innovative biotechnology products	Director/Miembro de la Junta	10/03/2010
Matignon Investissement et Gestion SAS Matignon Investissement et Gestion SAS Investment ManagersFinance MIG is an active private equity investment manager with a long-term outlook. Originally investing across a variety of industries, the firm has progressively focused on sectors including medical technology, healthcare-related services and biotechnology. They also invest in the information and communication technology sector, and their expansion financing and LBO activities are not sector-specific. MIG acquires significant minority stakes in French, European and US companies, balancing their investments across development stages. The firm targets companies based on a coherent commercial strategy and whose research efforts are mature. They seek board representation. Their exit strategies favor trade sales to large biomedical groups. MIG's specific interests within their sectors of expertise have included orthopedic implants for spinal surgery, nutritional counseling, biodegradable cardiovascular stents, surgical navigation systems, glucose measurement, sleep apnea and HIV non-progression.	Inversor de Capital Privado	21/01/2010
Xeltis AG Xeltis AG Medical SpecialtiesHealth Technology Develops medical devices for heart valve replacement and vascular surgery	Presidente	-
Galien Développement SA Galien Développement SA Miscellaneous Commercial ServicesCommercial Services Provides management and financial services to pharmacies	Director/Miembro de la Junta	-
Kaneka Eurogentec SA Kaneka Eurogentec SA BiotechnologyHealth Technology Distributes reagents, kits, and other related products for the biotechnology, pharmaceutical, and diagnostic sectors	Director/Miembro de la Junta	-

Ver el detalle de la experiencia de Guillaume Connan.

Formación de Guillaume Connan.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Guillaume Connan.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	10
Nautilus Biotech SA Nautilus Biotech SA Pharmaceuticals: MajorHealth Technology Develops and markets innovative biotechnology products	Health Technology
Matignon Investissement et Gestion SAS Matignon Investissement et Gestion SAS Investment ManagersFinance MIG is an active private equity investment manager with a long-term outlook. Originally investing across a variety of industries, the firm has progressively focused on sectors including medical technology, healthcare-related services and biotechnology. They also invest in the information and communication technology sector, and their expansion financing and LBO activities are not sector-specific. MIG acquires significant minority stakes in French, European and US companies, balancing their investments across development stages. The firm targets companies based on a coherent commercial strategy and whose research efforts are mature. They seek board representation. Their exit strategies favor trade sales to large biomedical groups. MIG's specific interests within their sectors of expertise have included orthopedic implants for spinal surgery, nutritional counseling, biodegradable cardiovascular stents, surgical navigation systems, glucose measurement, sleep apnea and HIV non-progression.	Finance
Kaneka Eurogentec SA Kaneka Eurogentec SA BiotechnologyHealth Technology Distributes reagents, kits, and other related products for the biotechnology, pharmaceutical, and diagnostic sectors	Health Technology
École des Hautes Études Commerciales de Paris École des Hautes Études Commerciales de Paris Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
QIAGEN Marseille SA QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services Develops and markets molecular diagnostic tests for cancer	Commercial Services
Chabé Limousines SAS Chabé Limousines SAS Other TransportationTransportation Provides private chauffeur services	Transportation
Galien Développement SA Galien Développement SA Miscellaneous Commercial ServicesCommercial Services Provides management and financial services to pharmacies	Commercial Services
Helse SAS Helse SAS Investment ManagersFinance Acts as an alternative investment manager	Finance
Xeltis AG Xeltis AG Medical SpecialtiesHealth Technology Develops medical devices for heart valve replacement and vascular surgery	Health Technology
Connan Bonvallet Conseil Connan Bonvallet Conseil Miscellaneous Commercial ServicesCommercial Services Provides business and management consulting services	Commercial Services